TRINITY BIOTECH PLC (TRIB) Form 6-K — Jun 12, 2026
Trinity Biotech plc entered into an At-The-Market Offering Agreement with Lucid Capital Markets, LLC, authorizing the sale of up to $4,352,314 of its American Depositary Shares (ADSs). Each ADS represents 20 of the company’s A Ordinary Shares, and Lucid will act as sales agent, receiving a 3.0% commission on gross sales proceeds. The company simultaneously terminated its previous ATM agreement with Craig-Hallum Capital Group LLC, which had been inactive since March 2025. The new offering is conducted pursuant to an existing effective Form F-3 shelf registration statement filed in June 2023.
Key figures
- Commission Rate
- 3
- Offering Capacity
- 4352314
- Ads Ratio
- 1 ADS represents 20 Ordinary Shares
- Max Ads Authorized
- 50000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.